CPRX

FIRDAPSE®(Amifampridine)

Lambert-Eaton myasthenic syndrome (LEMS)

Quarterly Sales (Approved)

Exp Date

TBD

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: FIRDAPSE®(Amifampridine) for Lambert-Eaton myasthenic syndrome (LEMS) - Quarterly Sales (Approved)


WHAT IS THE NEXT CATALYST EVENT?

  • Updates on Patent Litigation 


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION

  • Firdapse® (amifampridine) 10 mg tablets is an oral, nonspecific, voltage-dependent, potassium (K+) channel blocker that causes depolarization of the presynaptic membrane and slows or inhibits repolarization. This action results in the opening of slow voltage-dependent calcium (Ca2+) channels, allowing for a subsequent influx of Ca2+. In turn, it induces the exocytosis of synaptic vesicles containing Acetylcholine (ACh) to release more ACh into the synaptic cleft, enhancing neuromuscular transmission, and providing for improved muscle function.

Updated by JM 

CPRX, Catalyst Pharma, Lambert-Eaton myasthenic syndrome (LEMS), Litigation, FIRDAPSE (Amifampridine)

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon